Dave Ricks

Dave Ricks became CEO of Eli Lilly in 2017, but has been working at different departments within the company since 1996. The last few years have certainly been turbocharged. Eli Lilly got the green light from the FDA to sell a diabetes drug as a weight-loss medication called Zepbound in 2023; that helped the company bring in $34 billion in revenue in fiscal year 2023, up nearly 20% from the previous year. In 2024, Eli Lilly announced it would be investing an extra $5.3 billion into expanding manufacturing capabilities for the product.